Not provided
Not provided
Not provided
Not provided
Not provided
Mainly due to insufficient recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Stiftung Swiss Tumor Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
The study investigates the influence of the use of a Smartphone App, on changes in general well-being and the occurrence of symptoms during a tumor therapy. With this documentation, medical professionals should be enabled to judge the influence of symptoms on quality of life during different time periods, between planed visits on site.
The study will examine the number, characteristics and intensity of electronically reported symptoms and therapy side effects depending on treatment and characteristics of patients with cancer of breast, colon, prostate, lung and hematological malignancies during a three-month period from the initiation of therapy. This period frequently represents the duration of a therapeutic regimen.
The level of agreement κ between the ECOG/CTCAE ratings by physicians at the time of the regular consultation, and the ratings derived from the daily PROs between consultations, will be analyzed in order to determine the reliability and utility of self-reported electronic symptom monitoring.
The purpose is to evaluate different qualities of symptoms self-reported electronically between consultations with respect to the course of treatment application, out-patient settings, gender and age. In particular, outpatients with frequent (weekly) consultations will be compared to patients with infrequent consultations (3-weekly or less frequent).
The study will also aim to identify the conditions and factors that might increase the likelihood of an unplanned consultation or emergency hospitalization.
In particular, the proposed study design and associated primary and secondary endpoints will enable us to test the following hypotheses:
Patients with the most common types of cancer in the treatment center will be included:
Breast, Colon, Prostate, Lung, Hematological malignancies
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Consilium-APP | Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| app | Device | The app is used to record the study parameters for a period of 90 days. The following measures are used for data collection:
After completion of the study patients will be questioned according to: • Usability and usefulness of the Smartphone app |
| Measure | Description | Time Frame |
|---|---|---|
| Level of agreement | Level of agreement κ with respect to categories of common toxicity criteria (ECOG/CTCAE) categories between ePRO recording and the treating physician at time of consultation | 12 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| ePRO and therapy side effects | Assessment of the number, characteristics and intensity of electronically reported symptoms and therapy side effects during the first three months of therapy | 12 weeks of treatment |
| Rating of different qualities of electronically reported symptoms in out-patient settings |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with the most common types of cancer in the treatment center will be included: Breast, Colon, Prostate, Lung, Hematological malignancies
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andreas Trojan, Prof. Dr. med. | OnkoZentrum Zürich AG | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| LKH Feldkirch, Innere Medizin II | Feldkirch | 6807 | Austria | |||
| Universitätsklinikum Halle (Saale) Universitätsklinik und Poliklinik für Gynäkologie |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38710048 | Derived | Trojan A, Kuhne C, Kiessling M, Schumacher J, Drose S, Singer C, Jackisch C, Thomssen C, Kullak-Ublick GA. Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data. JMIR Form Res. 2024 May 6;8:e55917. doi: 10.2196/55917. | |
| 38573759 |
Not provided
Not provided
Not provided
2020/2021
Not provided
Not provided
Not provided
Not provided
Not provided
|
Rating of different qualities of electronically reported symptoms in out-patient settings with respect to: course of treatment application (oral vs. infusion vs. radiation), treatment (systemic vs. local), gender and age |
| 12 weeks of treatment |
| Unplanned consultations | Number and nature of unplanned consultations, (consultation vs. emergency hospitalizations) | 12 weeks of treatment |
| Hospital days | Number of days in the hospital during for each event (≤2 days or > 2 days) | 12 weeks of treatment |
| Patient characteristics for discontinued use of mobile monitoring | Assessment of patients' characteristics for a discontinuation of the use of the mobile monitoring | 12 weeks of treatment |
| Usability and usefulness of smartphone app | Evaluation of the usability and usefulness of the smartphone app in the course of the treatment as rated by physician and patient after completion of the study | 12 weeks of treatment |
| Halle |
| 06120 |
| Germany |
| Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie) | Lübeck | 23538 | Germany |
| Sana Klinikum Offenbach Abteilung Gynäkologie und Geburtshilfe | Offenbach | 63069 | Germany |
| OnkoZentrum Zürich AG | Zurich | Canton of Zurich | 8038 | Switzerland |
| Kantonsspital Aarau | Aarau | 5000 | Switzerland |
| Tumor Zentrum Aarau - Hirslanden Medical Center | Aarau | 5000 | Switzerland |
| Onkologie Praxis Lindenhofspital | Bern | 3001 | Switzerland |
| PROLINDO - Lindenhofspital | Bern | 3001 | Switzerland |
| Oncocare Klinik Engeried | Bern | 3012 | Switzerland |
| TUCARE | Bülach | 8180 | Switzerland |
| Onko-Hämatologisches Zentrum Zug | Cham | 6330 | Switzerland |
| Kantonsspital Baselland | Liestal | 4410 | Switzerland |
| Limmattal Spital | Schlieren | 8952 | Switzerland |
| Onkologiepraxis Bellvue | Zurich | 8001 | Switzerland |
| Brust-Zentrum Zürich | Zurich | 8008 | Switzerland |
| OnkoZentrum Hirslanden | Zurich | 8032 | Switzerland |
| Universitätsspital Zürich, Klinik für Gynäkologie | Zurich | 8091 | Switzerland |
| Derived |
| Trojan A, Roth S, Atassi Z, Kiessling M, Zenhaeusern R, Kadvany Y, Schumacher J, Kullak-Ublick GA, Aapro M, Eniu A. Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes. JMIR Cancer. 2024 Apr 4;10:e54178. doi: 10.2196/54178. |
| 34383675 | Derived | Trojan A, Leuthold N, Thomssen C, Rody A, Winder T, Jakob A, Egger C, Held U, Jackisch C. The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial. J Med Internet Res. 2021 Aug 5;23(8):e29271. doi: 10.2196/29271. |
| 33729162 | Derived | Trojan A, Battig B, Mannhart M, Seifert B, Brauchbar MN, Egbring M. Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study. JMIR Cancer. 2021 Mar 17;7(1):e26950. doi: 10.2196/26950. |